Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





Yale Researchers Use Single-Cell Analysis and Machine Learning to Identify Major COVID-19 Target

By HospiMedica International staff writers
Posted on 30 May 2020
Scientists at the Yale School of Medicine (New Haven, CT, USA) are using single-cell RNA sequencing of infected human bronchial epithelial cells (HBECs) to learn how SARS-CoV-2 infects and alters healthy cells.

In the study, the scientists identified ciliated cells as the major target of SARS-CoV-2 infection. More...
The bronchial epithelium acts as a protective barrier against allergens and pathogens. Cilia removes mucus and other particles from the respiratory tract. Their findings offer insight into how the virus causes disease. The scientists infected HBECs in an air-liquid interface with SARS-CoV-2. Over a period of three days, they used single-cell RNA sequencing to identify signatures of infection dynamics such as the number of infected cells across cell types, and whether SARS-CoV-2 activated an immune response in infected cells.

The scientists utilized advanced algorithms to develop working hypotheses and used electron microscopy to learn about the structural basis of the virus and target cells. These observations provide insights about host-virus interaction to measure SARS-CoV-2 cell tropism, or the ability of the virus to infect different cell types, as identified by the algorithms. After three days, thousands of cultured cells became infected. The scientists analyzed data from the infected cells along with neighboring bystander cells. They observed ciliated cells were 83% of the infected cells. These cells were the first and primary source of infection throughout the study. The virus also targeted other epithelial cell types including basal and club cells. The goblet, neuroendocrine, tuft cells, and ionocytes were less likely to become infected.

The gene signatures revealed an innate immune response associated with a protein called Interleukin 6 (IL-6). The analysis also showed a shift in the polyadenylated viral transcripts. Lastly, the (uninfected) bystander cells also showed an immune response, likely due to signals from the infected cells. Pulling from tens of thousands of genes, the algorithms locate the genetic differences between infected and non-infected cells. In the next phase of this study, the scientists will examine the severity of SARS-CoV-2 compared to other types of coronaviruses, and conduct tests in animal models.

“Machine learning allows us to generate hypotheses. It’s a different way of doing science. We go in with as few hypotheses as possible. Measure everything we can measure, and the algorithms present the hypothesis to us,” said senior author David van Dijk, PhD, an assistant professor of medicine in the Section of Cardiovascular Medicine and Computer Science.

Related Links:
Yale School of Medicine


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Radiation Safety Barrier
RayShield Intensi-Barrier
Ureteral Dilatation Balloon
Dornier Equinox
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.